My Inner State

← More articles

November 13, 2026 · 3 min read

Microdosing and perimenopause: the promise, and the research catching up

Women in perimenopause are curious about microdosing, and science is finally paying attention. Here's the momentum, what's coming next, and what Inner State is building.

Women in perimenopause tell us a lot of the same things. They're sleeping badly. Their moods turn faster than they used to. Some days they don't quite feel like themselves. And they've heard a friend talk about microdosing and feeling "more like me again."

If you're curious too, that makes sense. Plenty of women are. What's new is that researchers are starting to ask the same questions.

Why so many women are curious

Women in their 40s are at the heart of this conversation. In a large survey of 6,193 psychedelic users, 68.4% of people who only microdosed were women, with an average age of 46.4, squarely in the perimenopause years. A nationally representative RAND study estimates about 11 million US adults used psilocybin in the past year, and 69% of them microdosed at least once.

Women's reasons often sound familiar. In a study of more than 8,700 people, women were more likely than men to say they microdose for their mood and to feel calmer.

"Microdosing" usually means a very small amount of a psychedelic, well below a dose that changes perception, taken on a regular schedule.

The momentum: research is catching up

For years, women in perimenopause were mostly left out of this research. That's changing.

  • Perimenopause is finally being studied. Researchers at Exeter have registered a study comparing wellbeing, stress and symptoms in perimenopausal women who use psychedelics and women who don't.
  • Women's experiences are being followed over time. King's College London and Hystelica are following women through the menopausal transition for 12 weeks to learn how their experience changes.
  • Hormones are part of the picture. A 2026 review explores how estradiol and progesterone may shape the way psychedelics work. In Auckland, researchers have published a plan for one of the first human studies of low-dose psilocybin across the menstrual cycle.
  • Encouraging mood research. In a double-blind, placebo-controlled trial in Zurich, 37 people with depression received one moderate dose of psilocybin or a placebo. Two weeks later, the psilocybin group had lower depression scores and a more positive view of themselves. This was a single larger dose given in a clinical setting, not a microdose, and it adds to a growing body of mood research.
  • Connection and wellbeing. A Stockholm study of 173 people at guided psilocybin retreats found wellbeing rose over the following 12 months. The strongest link was feeling more connected, followed by lower anxiety. The researchers observed people rather than comparing them with a placebo, and their findings echo something many women describe: feeling closer to themselves and to others.
  • Whole mushrooms are a new frontier. Mushrooms contain more than psilocybin. A mouse study found that a mushroom extract and synthetic psilocybin had different effects on measures linked to brain plasticity. That's an exciting reason to study whole mushrooms in people.

Researchers are also designing better-controlled studies, including new ways to account for expectations, like giving psilocybin during sleep, so women get clear answers.

Many women share powerful stories about this stage of life. Those stories are helping point researchers toward the questions that matter most.

Why quality and sourcing matter

Not all mushrooms are alike, and that's why quality is everything. This month, scientists reported that a mushroom called Galerina indica produces psilocybin alongside amatoxins, compounds that have no place in a wellness product. It's a clear example of why precise species identification and controlled sourcing are the foundation of any mushroom-based product worth trusting.

What Inner State is building

Inner State was founded on the belief that women deserve options designed for them and made with rigor. That means:

  • Verified species, so there's no question which mushroom it is
  • Controlled growing, for consistency from batch to batch
  • Testing, so what's inside is measured, not guessed

Our first whole-mushroom product is investigational and is being studied through formal research.

Perimenopause is a beginning, not an ending. The research is catching up to what women have been asking for, and we're proud to help build it.


For education only. Psilocybin is a Schedule I controlled substance under US federal law; its legal status varies by state and country. This article is not encouragement to obtain or use it, and is not medical advice. Inner State makes no claim that Adapt, microdosing or psilocybin treats, cures or prevents any condition. If you're in crisis, call or text 988 in the US.

← More articles · Open my check-in